Leishmaniasis - Current chemotherapy and recent advances in the search for novel drugs

Trends in Parasitology

Volumn 19, Issue 11, 2003, Pages 502-508

  Croft, Simon L ^a   Coombs, Graham H ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; BISPHOSPHONIC ACID DERIVATIVE; FLUCONAZOLE; IMIQUIMOD; IMMUNOMODULATING AGENT; ITRACONAZOLE; KETOCONAZOLE; LICOCHALCONE A; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAMIDRONIC ACID; PAROMOMYCIN; PENTAMIDINE; PX 6518; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; RISEDRONIC ACID; SITAMAQUINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; CHEMOTHERAPY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; EPIDEMIOLOGICAL DATA; HUMAN; IMMUNOMODULATION; NONHUMAN; OSTEOPOROSIS; PLASMA HALF LIFE; PREVALENCE; REVIEW; SKIN LEISHMANIASIS; TERATOGENICITY; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ANIMALIA; PROTOZOA;

EID: 0142258171     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2003.09.008     Document Type: Review

References (57)

1. Guerin P., et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect. Dis. 2:2002;494-501.
2. Davies C.R., et al. Leishmaniasis: new approaches to disease control. BMJ. 326:2003;377-382.
3. Zilberstein D. Transport of nutrients and ions across membranes of trypanosomatid parasites. Adv. Parasitol. 32:1993;261-291.
4. Burchmore R.J., Barrett M.P. Life in vacuoles-nutrient acquisition by Leishmania amastigotes. Int. J. Parasitol. 31:2001;1311-1320.
5. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health. 6:2001;849-854.
6. Berhe N., et al. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS. 13:1999;1921-1925.
7. WHO Model prescribing information: drugs used in parasitic diseases. 2nd edn: 1995;WHO, Geneva.
8. Moore E., et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull. World Health Organ. 79:2001;388-393.
9. Thakur C.P., et al. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans. R. Soc. Trop. Med. Hyg. 93:1999;319-323.
10. Berman J.D., et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. World Health Organ. 76:1998;25-32.
11. Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis. 28:1999;49-51.
12. Sundar S., et al. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ. 323:2001;419-422.
13. Bodhe P.V., et al. Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 93:1999;314-318.
14. Petit C., et al. Activity of heat-induced reformulation of amphotericin B deoxycholate (Fungizone) against Leishmania donovani. Antimicrob. Agents Chemother. 43:1999;390-392.
15. Croft S.L., et al. Antiprotozoal activities of phospholipid analogues. Mol. Biochem. Parasitol. 126:2003;165-172.
16. Sundar S., et al. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347:2002;1739-1746.
17. Soto J., et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect Dis. 33:2001;E57-E61.
18. Yeates C. Sitamaquine (GlaxoSmithKline / Walter Reed Army Institute). Curr. Opin. Investig. Drugs. 3:2002;1446-1452.
19. Dietze R., et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am. J. Trop. Med. Hyg. 65:2001;685-689.
20. Thakur C.P., et al. Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans. R. Soc. Trop. Med. Hyg. 94:2000;432-433.
21. El-On J., et al. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J. Am. Acad. Dermatol. 27:1992;227-231.
22. Soto J., et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study. Am. J. Trop. Med. Hyg. 66:2002;147-151.
23. Garnier T., Croft S.L. Topical treatment for cutaneous leishmaniasis. Curr. Opin. Investig. Drugs. 3:2002;538-544.
24. Koutinas A.F., et al. A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniasis. Vet. Parasitol. 98:2001;247-261.
25. Navin T.R., et al. Placebo-controlled trial of sodium stibogluconate (Pentostam) versus ketoconazole in Guatemala. J. Infect Dis. 165:1992;528-534.
26. Al-Abdely H.M., et al. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniasis. Antimicrob. Agents Chemother. 43:1999;2910-2914.
27. Rodriguez N., et al. Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate. J. Infect Dis. 186:2002;138-140.
28. Yardley V., et al. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob. Agents Chemother. 46:2002;929-931.
29. Martin M.B., et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Toxoplasma gondii and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem. 44:2001;909-916.
30. Zhai L., et al. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J. Antimicrob. Chemother. 43:1999;793-803.
31. Fournet A., et al. In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of New World cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrob. Agents Chemother. 40:1996;2447-2451.
32. Olliaro P., et al. Developments in the treatment of leishmaniasis and trypanosomiasis. Expert Opin. Emerging Drugs. 7:2002;1-7.
33. Murray H.W., et al. Requirement for T cells and effects of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J. Clin. Invest. 83:1989;1253-1257.
34. Alvar J., et al. Leishmania and human immunodeficiency virus co-infection: the first 10 years. Clin. Microbiol. Rev. 10:1997;298-319.
35. Buates S., Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J. Infect Dis. 179:1999;1485-1494.
36. Arevalo I., et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect Dis. 33:2001;1847-1851.
37. Lopez-Jaramillo P., et al. Treatment of cutaneous leishmaniasis with nitric oxide donor. Lancet. 351:1998;1176-1177.
38. Smith A., et al. Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis. Antimicrob. Agents Chemother. 44:2000;1494-1498.
39. Awasthi A., et al. CD40 signaling is impaired by L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response. J. Exp. Med. 197:2003;1037-1043.
40. Barrett M.P., et al. Recent advances in identifying and validating drug targets in trypanosomes and leishmanias. Trends Microbiol. 7:1999;82-88.
41. Fries D.S., Fairlamb A.H. Antiprotozoal agents. Abraham D.J. 6th edn Burger's Medicinal Chemistry and Drug Discovery. Vol. 5:2003;1033-1087 John Wiley & Sons.
42. Sajid M., McKerrow J.R. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. 120:2002;1-21.
43. Roberts C.W., et al. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol. 126:2003;129-142.
44. Gilbert I.H. Inhibitors of dihydrofolate reductase in Leishmania and trypanosomes. Biochim. Biophys. Acta. 1587:2002;249-257.
45. Cunningham M.L., Beverley S.M. Pteridine salvage throughout the Leishmania infectious cycle: implications for antifolate chemotherapy. Mol. Biochem. Parasitol. 113:2001;199-213.
46. Gelb M.H., et al. Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol. Biochem. Parasitol. 126:2003;155-163.
47. Verlinde C.L., et al. Glycolysis as a target for the design of new anti-trypanosome drugs. Drug Resist. Updat. 4:2001;50-65.
48. Müller S., et al. Targeting polyamines of parasitic protozoa in chemotherapy. Trends Parasitol. 17:2001;242-249.
49. Doerig C., et al. Protein kinases as drug targets in parasitic protozoa. Trends Parasitol. 18:2002;366-371.
50. Havens C.G., et al. Cellular effects of leishmanial tubulin inhibitors on L. donovani. Mol. Biochem. Parasitol. 110:2000;223-236.
51. Jayanarayan K.G., Dey C.S. Microtubules: dynamics, drug interaction and drug resistance in Leishmania. J. Clin. Pharm. Ther. 27:2002;313-320.
52. Roberts W.L., et al. Characterization of the antimonial antileishmanial agent meglumine antimonate (Glucantime). Antimicrob. Agents Chemother. 42:1998;1076-1082.
53. Zilberstein D., Ephros M. Clinical and laboratory aspects of Leishmania chemotherapy in the area of drug resistance. Black S.J., Seed J.R. World Class Parasites. Vol. 4:2002;115-136 Kluwer Academic Press, London.
54. Pathak M.K., Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. 167:2001;3391-3397.
55. Croft S.L., Yardley V. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 8:2002;319-342.
56. Croft S.L. Monitoring drug resistance in leishmaniasis. Trop. Med. Int. Health. 6:2001;899-905.
57. Lira R., et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect Dis. 180:1999;564-567.